Mohammed S. Taghour

1.5k total citations
33 papers, 1.3k citations indexed

About

Mohammed S. Taghour is a scholar working on Organic Chemistry, Molecular Biology and Toxicology. According to data from OpenAlex, Mohammed S. Taghour has authored 33 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Organic Chemistry, 21 papers in Molecular Biology and 12 papers in Toxicology. Recurrent topics in Mohammed S. Taghour's work include Synthesis and biological activity (19 papers), Bioactive Compounds and Antitumor Agents (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Mohammed S. Taghour is often cited by papers focused on Synthesis and biological activity (19 papers), Bioactive Compounds and Antitumor Agents (12 papers) and Angiogenesis and VEGF in Cancer (12 papers). Mohammed S. Taghour collaborates with scholars based in Egypt, Saudi Arabia and United States. Mohammed S. Taghour's co-authors include Ibrahim H. Eissa, Eslam B. Elkaeed, Hazem Elkady, Ahmed M. Metwaly, Hazem A. Mahdy, Alaa Elwan, Ahmed B. M. Mehany, Mohammed A. Dahab, Nehal M. El‐Deeb and Mohamed S. Alesawy and has published in prestigious journals such as PLoS ONE, Molecules and RSC Advances.

In The Last Decade

Mohammed S. Taghour

33 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mohammed S. Taghour Egypt 21 911 701 246 231 158 33 1.3k
Helmy Sakr Egypt 21 1.0k 1.1× 689 1.0× 187 0.8× 222 1.0× 101 0.6× 39 1.4k
Hazem A. Mahdy Egypt 21 1.2k 1.3× 870 1.2× 291 1.2× 270 1.2× 158 1.0× 48 1.7k
Mohammed A. Dahab Egypt 16 639 0.7× 550 0.8× 197 0.8× 182 0.8× 174 1.1× 37 1.1k
Alaa Elwan Egypt 18 629 0.7× 545 0.8× 212 0.9× 181 0.8× 111 0.7× 37 992
Abdel‐Ghany A. El‐Helby Egypt 19 869 1.0× 576 0.8× 164 0.7× 180 0.8× 86 0.5× 20 1.2k
Reda G. Yousef Egypt 17 533 0.6× 496 0.7× 198 0.8× 158 0.7× 167 1.1× 41 875
Ashraf H. Bayoumi Egypt 25 1.1k 1.2× 538 0.8× 89 0.4× 156 0.7× 141 0.9× 50 1.4k
Hazem Elkady Egypt 30 1.5k 1.6× 1.3k 1.8× 454 1.8× 443 1.9× 350 2.2× 94 2.3k
Mostafa A. Elhendawy Egypt 13 626 0.7× 444 0.6× 162 0.7× 123 0.5× 117 0.7× 20 950
Rezk R. Ayyad Egypt 25 1.1k 1.2× 691 1.0× 119 0.5× 174 0.8× 98 0.6× 52 1.5k

Countries citing papers authored by Mohammed S. Taghour

Since Specialization
Citations

This map shows the geographic impact of Mohammed S. Taghour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed S. Taghour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed S. Taghour more than expected).

Fields of papers citing papers by Mohammed S. Taghour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mohammed S. Taghour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed S. Taghour. The network helps show where Mohammed S. Taghour may publish in the future.

Co-authorship network of co-authors of Mohammed S. Taghour

This figure shows the co-authorship network connecting the top 25 collaborators of Mohammed S. Taghour. A scholar is included among the top collaborators of Mohammed S. Taghour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mohammed S. Taghour. Mohammed S. Taghour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elkady, Hazem, Hazem A. Mahdy, Mohammed S. Taghour, et al.. (2024). New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies. Biochimica et Biophysica Acta (BBA) - General Subjects. 1868(6). 130599–130599. 13 indexed citations
2.
El‐Metwally, Souad A., Hazem Elkady, Eslam B. Elkaeed, et al.. (2024). New modified thieno[2,3-d]pyrimidine derivatives as VEGFR-2 inhibitors: Design, synthesis, in vitro anti-cancer evaluation and divers in silico studies. Journal of Molecular Structure. 1302. 137465–137465. 7 indexed citations
3.
Elkady, Hazem, Mohammed S. Taghour, Mohammed A. Dahab, et al.. (2023). New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies. Computational Biology and Chemistry. 107. 107958–107958. 16 indexed citations
4.
Abdallah, Abdallah E., et al.. (2023). Design, synthesis, anticancer evaluation, and in silico ADMET analysis of novel thalidomide analogs as promising immunomodulatory agents. RSC Advances. 13(16). 10488–10502. 20 indexed citations
5.
El‐Metwally, Souad A., Hazem Elkady, Aly F. Mohamed, et al.. (2023). Discovery of New VEGFR-2 Inhibitors and Apoptosis inducer-based thieno[2,3- d ]pyrimidine. Future Medicinal Chemistry. 15(22). 2065–2086. 6 indexed citations
6.
El‐Metwally, Souad A., Hazem Elkady, Mohamed Hagras, et al.. (2023). Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-d]pyrimidines targeting VEGFR-2. RSC Advances. 13(33). 23365–23385. 15 indexed citations
7.
Mahdy, Hazem A., Hazem Elkady, Mohammed S. Taghour, et al.. (2023). New Theobromine Derivatives Inhibiting VEGFR-2: Design, Synthesis, Antiproliferative, Docking and Molecular Dynamics Simulations. Future Medicinal Chemistry. 15(14). 1233–1250. 24 indexed citations
8.
Elkady, Hazem, Alaa Elwan, Mohammed S. Taghour, et al.. (2023). Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2,4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC Advances. 13(40). 27801–27827. 16 indexed citations
9.
Taghour, Mohammed S., Hazem Elkady, Wagdy M. Eldehna, et al.. (2023). Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies. Journal of Biomolecular Structure and Dynamics. 41(21). 11535–11550. 41 indexed citations
10.
Elwan, Alaa, Abdallah E. Abdallah, Hazem A. Mahdy, et al.. (2022). Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation. Molecules. 27(15). 5047–5047. 51 indexed citations
11.
Taghour, Mohammed S., Hazem A. Mahdy, Alaa Elwan, et al.. (2022). Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, in silico studies, and antiproliferative evaluation. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 2063–2077. 43 indexed citations
12.
Taghour, Mohammed S., Hazem Elkady, Wagdy M. Eldehna, et al.. (2022). Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway. PLoS ONE. 17(9). e0272362–e0272362. 40 indexed citations
13.
Elkaeed, Eslam B., Mohammed S. Taghour, Hazem A. Mahdy, et al.. (2022). New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 2191–2205. 58 indexed citations
14.
Alanazi, Mohammed M., Alaa Elwan, Nawaf A. Alsaif, et al.. (2021). Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 36(1). 1732–1750. 45 indexed citations
15.
Alesawy, Mohamed S., Abdallah E. Abdallah, Mohammed S. Taghour, et al.. (2021). In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (Mpro). Molecules. 26(9). 2806–2806. 53 indexed citations
16.
Alsaif, Nawaf A., Mohammed S. Taghour, Mohammed M. Alanazi, et al.. (2021). Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. Journal of Enzyme Inhibition and Medicinal Chemistry. 36(1). 1093–1114. 57 indexed citations
17.
Alsaif, Nawaf A., Hazem A. Mahdy, Mohammed M. Alanazi, et al.. (2021). Targeting VEGFR‐2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Archiv der Pharmazie. 355(2). e2100359–e2100359. 21 indexed citations
18.
Alsaif, Nawaf A., Mohammed S. Taghour, Mohammed M. Alanazi, et al.. (2021). Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. Bioorganic & Medicinal Chemistry. 46. 116384–116384. 32 indexed citations
19.
Elkady, Hazem, Alaa Elwan, Hesham A. El‐Mahdy, et al.. (2021). New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies. Journal of Enzyme Inhibition and Medicinal Chemistry. 37(1). 403–416. 112 indexed citations
20.
Alesawy, Mohamed S., Ahmed A. Al‐Karmalawy, Eslam B. Elkaeed, et al.. (2020). Design and discovery of new 1,2,4‐triazolo[4,3‐c]quinazolines as potential DNA intercalators and topoisomerase II inhibitors. Archiv der Pharmazie. 354(3). e2000237–e2000237. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helmy Sakr Breakdown of academic impact, for papers by Hazem A. Mahdy Breakdown of academic impact, for papers by Mohammed A. Dahab Breakdown of academic impact, for papers by Alaa Elwan Breakdown of academic impact, for papers by Abdel‐Ghany A. El‐Helby Breakdown of academic impact, for papers by Reda G. Yousef Breakdown of academic impact, for papers by Ashraf H. Bayoumi Breakdown of academic impact, for papers by Hazem Elkady Breakdown of academic impact, for papers by Mostafa A. Elhendawy Breakdown of academic impact, for papers by Rezk R. Ayyad
Rankless by CCL
2026